论文部分内容阅读
目的:研究XRCC1基因多态性与非小细胞肺癌(NSCLC)患者对铂类为基础的联合化疗的敏感性。方法:收集我院NSCLC患者54例,提取外周白细胞DNA,采用多重PCR对XRCC1 194,399两个多态性位点同时扩增,对扩增产物进行纯化后直接测序,判定基因分型。结果:携带XRCC1 399 Arg/Arg的化疗有效率是Gln/Gln的2.5倍(P=0.035,95%CI=0.892～7.094)。携带一个Gln等位基因的化疗失败风险是携带Arg/Arg的1.7倍(P=0.044,95%CI=1.012～2.720)。未发现XRCC1 194不同基因型对铂类化疗敏感性有差异。结论:XRCC1 399Gln/Arg基因多态性与晚期NSCLC接受铂类为基础的化疗敏感性相关。
PURPOSE: To investigate the sensitivity of platinum-based combination chemotherapy in patients with XRCC1 gene polymorphism and non-small cell lung cancer (NSCLC). Methods: Totally 54 patients with NSCLC in our hospital were collected. Peripheral leukocyte DNA was extracted. Multiplex PCR was used to amplify the two polymorphic sites of XRCC1, 194 and 399. The amplified products were directly sequenced and the genotypes were determined. Results: The effective rate of chemotherapy with XRCC1 399 Arg / Arg was 2.5 times that of Gln / Gln (P = 0.035, 95% CI = 0.892-7.094). The risk of failure of chemotherapy with a Gln allele was 1.7-fold greater with Arg / Arg (P = 0.044, 95% CI = 1.012-2.720). There was no difference in the sensitivity of different genotypes of XRCC1 194 to platinum chemotherapy. Conclusion: The polymorphism of XRCC1 399Gln / Arg gene is associated with the sensitivity to platinum-based chemotherapies in advanced NSCLC.